Editorial from Biotech Daily, page-91

Great tilt, I am an avid watcher of the machinations and hurting like everyone else left holding a large capital loss. From the news releases about substantial holdings changes up to the NASDAQ listing those crew at JPM/Credit Suisse where all over the stock,its quite a tangled web and I'm only new to trying to see thru all the Stock borrowing agreements and work out who actually lent stock to who for whatever reason. From what I see all the flurry was to lock up stock for the NASDAQ listing by the brokers?
The stock has seen some decent parcels move into what I would call quality hands this year ie Thorney, Capital Group as well as Celgene. Understandably all these holders must be smarting as well, or was it them who have decided to bail out?
From the information I can get access to around 7-8% of the stock is held in short positions, seeing the SP action this week I am quite surprised to see only the following short trades as % of daily volumes:

	Column 1	Column 2	Column 3	Column 4	Column 5	Column 6
0	Date	Gross shorts 1	Issued capital	% Capital shorted 2	Trade volume 3	Shorts as % of volume
1	Thu 19th Nov, 2015	336,545	337,420,632	0.10%	2,301,376	14.62%
2	Wed 18th Nov, 2015	333,958	337,285,632	0.09%	2,319,943	14.40%
3	Tue 17th Nov, 2015	630,807	337,285,632	0.18%	4,188,728	15.06%
4	Mon 16th Nov, 2015	1,048,819	337,285,632	0.31%	5,547,914	18.90%

With no real signal via "sub holder" changes there doesn't seem to be the usual suspects holding a large short position in the stock, [insert UBS,Credit Suisse,MaQbank] and they didn't really do a large buy back in to return the borrowed stock during this recent rout. Let me know if you can see otherwise.
The rebalance of the share price after the NASDAQ listing once trading began again on the ASX is really to reflect the complete lack of interest and support for the stock in US [and price ratio]. This is puzzling as well as disturbing knowing that Celgene, Teva which are well recognised names in the business already have their hands,skin in. So why the lack of support into a ground-breaking gamechanger such as stemcells? This I cannot answer and so it looks neither can the board of MSB. I have emailed them this week but yet to see a response, but I'm sure their inbox's are overflowing with please explain correspondence.
Opportunities to short stock knowing that a capital raising is coming are a large flag usually and also the circumstances that would see a re-rating of a stock or position change due to capitalisation value out of the ASX 100,200,300. From what I can see this was a missed opportunity for the shorters?
Again being new to the whole forensic information trail of who is holding and what position, this is all IMO.
Sometimes there are that many entities of the same initial Sub holder, its a confusing and quite frustrating trail to follow for the layman. I think I am not alone with this problem. Seeing Global Master security lending agreements and AMSLA agreements I'm always doing what I can to track whether the brokers/insto's involved are selling/buying/returning/borrowing to gauge the SP momentum.
Well to conclude I am eagerly awaiting either a response to my email or news from the board as to "why,where to from here".
Happy trading.